Postexposure prophylaxis against prion disease with a stimulator of innate immunity.
Abstract
The absence of an immune response to prions--the infectious agents of scrapie, bovine spongiform encephalopathy (BSE), and Creutzfeldt-Jakob disease--might be related to the fact that these agents do not contain nucleic acids. We aimed to use CpG oligodeoxynucleotides, which have been shown to stimulate innate immunity, as a form of postexposure prophylaxis in mice. We inoculated healthy mice with brain homogenates from mice infected with the RML scrapie prion, and then injected CpG oligodeoxynucleotides. This postexposure prophylaxis with CpG oligodeoxynucleotides resulted in 38% longer survival times than treatment with saline (p<0.0001), or even longer after repeated application. The explanation for this finding remains to be elucidated, but the most likely is stimulation of TLR9-expressing cells of the innate immune system such as macrophages, monocytes, and dendritic cells. CpG oligodeoxynucleotides have not been shown to have adverse effects to human health and could therefore be considered as a therapeutic choice in postexposure prophylaxis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Un-methylated CpG DNA, an agonist of TLR9 signaling, prolongs scrapie incubation period in mice.
“Un-methylated CpG DNA, which is an agonist of TLR9 signaling, has been shown to prolong the scrapie incubation period in mice, suggesting that innate immune activation can interfere with prion disease progression [9], [10].”
From MicroRNA 146a (miR-146a) Is Over-Expressed during Prion Disease and Modulates the Innate Immune Response and the Microglial Activation State (2012) · cites this paper as [9]
Cited by
Sorted by citations
Heikenwalder, M., Polymenidou, M., Junt, T., Sigurdson, C., Wagner, H., Akira, S., Zinkernagel, R., & Aguzzi, A. (2004) · Nature Medicine · doi:10.1038/nm987 · Cited by 449 · see citing works
Self-citationPathogenesis of prion diseases: current status and future outlook
Aguzzi, A., & Heikenwalder, M. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1492 · Cited by 207 · see citing works
Saba, R., Gushue, S., Huzarewich, R. L. C. H., Manguiat, K., Medina, S., Robertson, C., & Booth, S. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030832 · Cited by 151 · see citing works
Aguzzi, A., & Zhu, C. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90605 · Cited by 122 · see citing works
Prion pathogenesis in the absence of Toll-like receptor signalling
Prinz, M., Heikenwalder, M., Schwarz, P., Takeda, K., Akira, S., & Aguzzi, A. (2003) · The EMBO Reports · doi:10.1038/sj.embor.embor731 · Cited by 85 · see citing works
Toll-like receptor 2 confers partial neuroprotection during prion disease
Carroll, J. A., Race, B., Williams, K., & Chesebro, B. (2018) · PLOS ONE · doi:10.1371/journal.pone.0208559 · Cited by 22 · see citing works
- Authors
- Sethi, S., Lipford, G., Wagner, H., & Kretzschmar, H.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-07
- Volume
- 360
- Issue
- 9328
- Pages
- 229-230
- ISSN
- 0140-6736
- Cited by
- 112
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review